MRSN

Mersana Therapeutics
MRSN

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$39.74M
EV
$-66.22M
Shares Outstanding
124.63M
Beta
1.30

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$4.57
P/E 2025E
-
P/Revenue 2025E
1.44x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Mersana Therapeutics, Inc.

gainify
MRSN

Mersana Therapeutics, Inc.

MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has ...

Sector

Healthcare

Industry

Biotechnology

CEO

Huber, Martin

Employees

102

IPO Date

2017-06-28

Headquarters

840 Memorial Drive, Cambridge, Massachusetts, 02139, United States

gainify
mailcontactcontact
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.